These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17584045)

  • 21. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.
    Schiffrin EL; Amiri F; Benkirane K; Iglarz M; Diep QN
    Hypertension; 2003 Oct; 42(4):664-8. PubMed ID: 12874098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PPARgamma activity in the vessel wall: anti-atherogenic properties.
    Reiss AB; Vagell ME
    Curr Med Chem; 2006; 13(26):3227-38. PubMed ID: 17168709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.
    Chinetti G; Fruchart JC; Staels B
    Z Kardiol; 2001; 90 Suppl 3():125-32. PubMed ID: 11374025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.
    Plutzky J
    Curr Atheroscler Rep; 2000 Jul; 2(4):327-35. PubMed ID: 11122762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Staels B; Fruchart JC
    Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
    Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y
    J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway.
    Zhang Y; Zhan RX; Chen JQ; Gao Y; Chen L; Kong Y; Zhong XJ; Liu MQ; Chu JJ; Yan GQ; Li T; He M; Huang QR
    Eur J Pharmacol; 2015 May; 754():41-51. PubMed ID: 25687252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Narrowing in on cardiovascular disease: the atheroprotective role of peroxisome proliferator-activated receptor gamma.
    Gerry JM; Pascual G
    Trends Cardiovasc Med; 2008 Feb; 18(2):39-44. PubMed ID: 18308193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease.
    Magri CJ; Gatt N; Xuereb RG; Fava S
    Expert Rev Cardiovasc Ther; 2011 Oct; 9(10):1279-94. PubMed ID: 21985541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J; Wójcicka G; Jamroz A
    Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferator-activated receptors in endothelial cell biology.
    Plutzky J
    Curr Opin Lipidol; 2001 Oct; 12(5):511-8. PubMed ID: 11561170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome proliferator-activated receptors and the cardiovascular system.
    Chen YE; Fu M; Zhang J; Zhu X; Lin Y; Akinbami MA; Song Q
    Vitam Horm; 2003; 66():157-88. PubMed ID: 12852255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
    Pershadsingh HA
    Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
    Benkirane K; Viel EC; Amiri F; Schiffrin EL
    Hypertension; 2006 Jan; 47(1):102-8. PubMed ID: 16344371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
    Roberts AW; Thomas A; Rees A; Evans M
    Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.
    Azhar S
    Future Cardiol; 2010 Sep; 6(5):657-91. PubMed ID: 20932114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.